No approval for Sputnik V vaccine yet; Drug authority seeks additional data from Dr Reddy’s

An expert panel of India’s central drug authority has sought additional data and information from Dr Reddy’s Laboratories, which has sought emergency use authorisation for Russian Covid-19 vaccine Sputnik V, while deferring its decision on it till the next meeting, sources said.

In light of a February 24 meeting of the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO), the firm presented the interim safety and immunogenicity data of the Gam-Covid-Vac combined vector vaccine generated in the country, along with the interim data from the ongoing Russian study.

According to the sources, the SEC, which deliberated on the EUA application on Thursday, recommended that the firm should present data pertaining to all immunogenicity parameters, unblinded data of serious adverse events and RT-PCR positive cases, along with causality analysis reported till date for further examination.

“It has also asked the Hyderabad-based firm to submit a comparative analysis of the phase 3 immunogenicity data generated on the Indian and Russian studies at various time points. It has also asked the drug-maker to submit the factsheet,” a source said.

“We have had our meeting with the SEC today and will await the feedback from the CDSCO. We will provide an update once we have the feedback,” Dr Reddy’s Laboratories said in a statement.

On February 19, the firm said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for Sputnik V.

In September last year, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod to two COVID-19 vaccines — Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia.

  • Related Posts

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    The Konkan division of Maharashtra ANTF raided three different locations in Bengaluru, during which the drug manufacturing units were busted. BENGALURU:  While the state government is aiming to make Karnataka…

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    New Delhi: A pharma group has sought extension for those production units that have already submitted upgradation plans and can demonstrate execution progress, even as the drug regulatory authority seems…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

    Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

    National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

    National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

    Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

    Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

    Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

    Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US